Company intelligence / Profile preview
Cingulate Inc.
Kansas City, Kansas, United Statescingulate.com ↗
- Ownership
- Public · CING
- Employees
- ~13
- Development stage
- Other
01
Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company developing innovative treatments for ADHD and anxiety using its proprietary Precision Timed Release platform. Its lead candidate, CTx‑1301 (dexmethylphenidate), has reached Phase 3 trials for ADHD. Other pipeline assets include CTx‑1302 (dextroamphetamine) in Phase 1/2 and Phase 3 for pediatric ADHD, and CTx‑2103 (buspirone) targeting anxiety disorders. The company’s approach aims to enable once-daily dosing with improved efficacy and tolerability compared to existing therapies[1][3][4].
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (dexmethylphenidate, dextroamphetamine, buspirone)[4]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Financials
- Market cap
- $61.7M
- Total revenue
- $0
- Enterprise value
- $39.5M
Beyond the preview
Go deeper on Cingulate Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cingulate Inc..